TRIAL DESIGN

The DAP-CORONA RCT is a phase III randomized, triple-blind, placebo-controlled multicentre study on the efficacy and safety of dapsone in adult patients who have been presenting with symptoms, have been diagnosed with COVID-19 infection and are at high risk of developing complications and requiring hospitalization. Approximately 2,100 individuals who meet the eligibility criteria of this trial will be selected to receive either dapsone, a generic drug, or placebo tablets for 21 days on a random basis.

Eligible participants will receive the trial medication delivered straight to their doorsteps. During the trial, they will be directly but remotely monitored and supported through the DAP-CORONA VirtualCare platform.

NOT ENROLLING CURRENTLY, ENROLLMENT TO START SOON.

MORE DETAILS WILL BE PROVIDED AT THE START OF THE CLINICAL TRIAL.

ELIGIBILITY

If you answer YES to all of the points below, you will be invited to contact the DAP-CORONA trial team to find out if you are eligible.

ELIGIBILITY

If you answer YES to all of the points below, you will be invited to contact the DAP-CORONA trial team to find out if you are eligible.

You are 40 years of age or over.

You are presenting symptoms of COVID-19 in the last four days [you have tested positive for COVID-19 or have submitted a test sample and waiting for the result or considering taking the COVID-19 test].

You live in Canada (Quebec or Ontario) or in the United States (Arizona, California, Florida or Pennsylvania).